ChiCTR2000033316 版本V1.2 版本创建时间2020/05/27 23:41:11 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000033316 

最近更新日期:

Date of Last Refreshed on:

2020-05-27 23:39:42 

注册时间:

Date of Registration:

2020-05-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

围手术期宫颈癌患者支持性照护移动医疗应用程序的可行性研究

Public title:

Study on the feasibility of mobile medical application program of supporting care for patients with cervical cancer in perioperative period

注册题目简写:

English Acronym:

研究课题的正式科学名称:

围手术期宫颈癌患者支持性照护移动医疗应用程序的开发及可行性研究

Scientific title:

Study on the feasibility of mobile medical application program of supporting care for patients with cervical cancer in perioperative period

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

夏丽莉 

研究负责人:

宋永霞 

Applicant:

Xia Lili 

Study leader:

Song Yongxia 

申请注册联系人电话:

Applicant telephone:

+86 18260095921

研究负责人电话:

Study leader's telephone:

+86 15956962431

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

704352540@QQ.COM

研究负责人电子邮件:

Study leader's E-mail:

1144211759@QQ.COM

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽合肥梅山路81号

研究负责人通讯地址:

安徽合肥梅山路81号

Applicant address:

81 Meishan Road, Hefei, Anhui, China

Study leader's address:

81 Meishan Road, Hefei, Anhui, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

安徽医科大学护理学院

Applicant's institution:

School of Nursing, Anhui Medical University

研究负责人所在单位:

安徽医科大学护理学院

Affiliation of the Leader:

School of Nursing, Anhui Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20170190

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

安徽医科大学生物医学伦理委员会

Name of the ethic committee:

Biomedical Ethics Committee of Anhui Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2017-03-01 00:00:00

伦理委员会联系人:

朱启星

Contact Name of the ethic committee:

Zhu Qixing

伦理委员会联系地址:

安徽合肥梅山路81号

Contact Address of the ethic committee:

81 Meishan Road, Hefei, Anhui, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

安徽医科大学护理学院

Primary sponsor:

School of Nursing, Anhui Medical University

研究实施负责(组长)单位地址:

安徽合肥梅山路81号

Primary sponsor's address:

81 Meishan Road, Hefei, Anhui, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

安徽医科大学护理学院

具体地址:

梅山路81号

Institution
hospital:

School of Nursing, Anhui Medical University

Address:

81 Meishan Road

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

安徽医科大学第一附属医院

具体地址:

蜀山区绩溪路218号

Institution
hospital:

The First Affiliated Hospital of Anhui Medical University

Address:

218 Jixi Road, Shushan District

经费或物资来源:

中华护理学会立项课题(ZHKY201812)

Source(s) of funding:

Chinese nursing association project (ZHKY201812)

Target disease:

Cervical cancer

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

半随机对照 

Study design:

Quasi-randomized controlled 

研究目的:

本研究拟在前期调查结果及文献回顾基础上,在软件开发团队支持下,形成宫颈癌围手术期患者支持性照护移动医疗APP的初始版本,组织专家会议,并招募患者对移动医疗APP进行可用性评价,根据反馈对APP进行修改和完善。最后以该移动医疗APP为手段进行可行性研究,评价其应用效果。最终旨在满足宫颈癌围手术期患者支持性照护需求,改善心理社会结局,提升生活质量。  

Objectives of Study:

On the basis of the previous investigation results and literature review, this study plans to form the initial version of the mobile medical app for supporting care of patients in the perioperative period of cervical cancer with the support of the software development team, organize expert meetings, recruit patients to evaluate the usability of the mobile medical app, and modify and improve the app based on the feedback. Finally, the feasibility of the mobile medical app is studied to evaluate its application effect. The final goal is to meet the needs of supportive care for patients with cervical cancer in perioperative period, improve the psychosocial outcome and improve the quality of life.

药物成份或治疗方案详述:

对照组:常规护理(入院当日介绍病区环境、主管医生、责任护士、管理制度、作息时间、安全宣教;入院1-3天介绍检查内容、饮食指导、用药指导等;术前1天介绍手术方式、术前准备等;术后对患者进行尿管护理、引流管注意事项、饮食指导、体位及生活指导等;盆底肌功能锻炼及性生活指导、下次复查时间及随访时间等;出院后1个月电话随访1次,长10分钟。) 干预组:支持性照护移动医疗APP干预和常规护理(入院当日介绍病区环境、主管医生、责任护士、管理制度、作息时间、安全宣教;入院1-3天介绍检查内容、饮食指导、用药指导等;术前1天介绍手术方式、术前准备等;术后对患者进行尿管护理、引流管注意事项、饮食指导、体位及生活指导等;盆底肌功能锻炼及性生活指导、下次复查时间及随访时间等;出院后1个月电话随访1次,长10分钟。)  

Description for medicine or protocol of treatment in detail:

Control group: Routine nursing (on the day of admission, the management system of responsible doctors and nurses in charge of the ward environment was introduced;1-3 days after admission, introduce the contents of the examination, such as dietary guidance, medication guidance, etc.1 day before the operation, the preoperative preparat E 

纳入标准:

①确诊为宫颈癌且接受手术治疗的患者;
②知晓自身病情;
③本人拥有一部Android系统手机并能上网;
④知情同意自愿参加研究;
⑤年龄为18岁及以上者

Inclusion criteria

1. Patients diagnosed as cervical cancer and received surgical treatment;
2. Patients who know their own conditions;
3. The patient has an Android mobile phone and can access the Internet;
4. Patients who voluntarily participated in the study with informed consent;
5. Patients aged 18 and above.

排除标准:

①为了研究结果的准确及研究实施的安全性,排除复发转移宫颈癌患者;
②听力、视力障碍者;
③合并严重慢性病,如严重心血管疾病、肝肾功能衰竭或其他类型癌症转移;
④合并精神疾病或者认知障碍;
⑤参与同类干预研究者

Exclusion criteria:

1. In order to ensure the accuracy of the research results and the safety of the research implementation, the patients with recurrent and metastatic cervical cancer were excluded;
2. Patients with hearing and vision disorders;
3. Patients with severe chronic diseases, such as severe cardiovascular disease, liver and kidney failure or other types of cancer metastasis;
4. Patients with mental illness or cognitive impairment;
5. Participants in similar intervention studies.

研究实施时间:

Study execute time:

From 2020-01-15 00:00:00 To 2021-01-15 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-06-15 00:00:00 To 2021-01-15 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

29

Group:

control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

Routine nursing

Intervention code:

组别:

干预组

样本量:

29

Group:

intervention group

Sample size:

干预措施:

支持性照护移动医疗APP干预和常规护理

干预措施代码:

Intervention:

Intervention of mobile medical APP for supportive care and routine nursing

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

合肥 

Country:

China 

Province:

Anhui 

City:

Hefei 

单位(医院):

安徽医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Anhui Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

支持性照护需求

指标类型:

主要指标

Outcome:

Needs for supportive care

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

负性情绪

指标类型:

次要指标

Outcome:

Negative emotion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

研究采取便利抽样法选自2020年6月-2021年2月入院患者,将符合纳排除标准的患者纳入研究,直至达到可行性研究样本量要求。避免同一个病房两组患者之间的沾染,按照入院顺序进行分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients who met the exclusion criteria are included in the study until the sample size of the feasibility study is reached. Contamination between two groups of patients in the same ward is avoided, and the patients are grouped in the order of admission

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

相关论文发表后,可在研究论文及Resman获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Relevant papers can be obtained from the research paper and Resman after publication

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质记录和电子记录相结合,研究负责人保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A combination of paper and electronic records is kept by the research leader

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-05-27 22:43:23